Crossmark

Genomic safety assessment and metabolic modulation by Enterococcus faecium 140,623, a probiotic strain from lactasin tablets: implications for obesity management

Crossref DOI link: https://doi.org/10.1007/s11274-026-04802-7

Published Online: 2026-02-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gan, Yongqi

Liu, Cheng

Zheng, Xiaorui

Nong, Jun

Fan, Lanyan

Xie, Peng

Li, Yang

Zhu, Bin

Ning, Ling

Zhang, Zan
Funding

Funding for this research was provided by:

the Drug Safety Research Project 2024 of Guangxi Drug Administration (No. 039)
License Information

Text and Data Mining valid from 2026-02-05

Version of Record valid from 2026-02-05
More Information

Article History

Received: 22 October 2025

Accepted: 12 January 2026

First Online: 5 February 2026

Declarations

:

: Animal experiments were approved and performed in accordance with the Laboratory Animal Ethic Committee of Guangxi Institute for Food and Drug Control (permit no. LLSC20231004-1). They were therefore performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below